In some chronic myeloid leukemia (CML) and AML, especially with high PTGDR2 expression in FAB subtypes M2, M3, and M6, patients showed better survival, suggesting that high PTGDR2 expression might be a target for leukemia therapy [51]. Here, PTGDR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.